The ELSA Study – childhood screening for type 1 diabetes

A UK study has found that screening for type 1 diabetes (T1D) in childhood can significantly increase early detection, and give families hope of delaying the need for insulin for years. 

Co-funded by Breakthrough T1D and Diabetes UK, and led by researchers at the University of Birmingham, the ELSA study used blood samples to identify biomarkers (antibodies) associated with type 1 diabetes that can appear years before symptoms.   

The ELSA (Early Surveillance for Autoimmune Diabetes) study is a green-light for a UK-wide screening programme that could transform how the disease is diagnosed and managed. ELSA 2 ha salready started, and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children and older teenagers. The research team aims to recruit 30,000 additional children across these new age groups.  

Medtechtomarket is proud to be working with the University of Birmingham and Breakthrough T1D to further improve the screening and management of this chronic autoimmune disease.

ELSA Study Findings

17,283 children aged 3-13 years old were screened for type 1 diabetes risk. The absence of antibodies would suggest the child is unlikely to develop T1D. Those identified with one antibody have a 15% chance of developing diabetes within 10 years. However, those found to have two or more antibodies are likely to have an immune system that has already begun attacking the insulin-producing cells in the pancreas. In these cases it is almost certain that the individual will eventually need insulin therapy.

From the 17,283 sample, 75 had one autoantibody, indicating future risk. 160 had two or more autoantibodies but did not yet require insulin therapy, indicating early-stage type 1 diabetes.  Seven were found to have undiagnosed type 1 diabetes – all needing to start insulin immediately.   

This means families can receive essential education and ongoing support. Early detection is key to this to avoid emergency diagnoses later on.

“This is about rewriting the story of type 1 diabetes for thousands of families. Instead of a devastating emergency, we can offer time, choices, and hope. By finding children in the earliest stages, we’re not just preparing families, we’re opening the door to treatments that can delay the need for insulin by years. That extra time means childhoods with fewer injections, fewer hospital visits and more normality. Thanks to research like ELSA, what once struck as an unexpected crisis can become an actively managed healthcare process, changing the course of T1D for the better.” 

– Rachel Connor, Director of Research Partnerships at Breakthrough T1D

The results of the study have been published in The Lancet. The findings mark a major step towards a future in which type 1 diabetes can be detected in children before symptoms appear. Currently, over one-in-four with type 1 diabetes don’t receive a diagnosis until they are already in diabetic ketoacidosis (DKA), a potentially fatal condition that requires urgent hospital treatment. Early detection can dramatically reduce emergency diagnoses and could give children access to new immunotherapy treatments that can delay the need for insulin for years. Rapid diagnosis of type 1 diabetes is essential to avoid life-threatening complications.